^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HYML-122

    i
    Other names: HYLM-122, HYML-122
    Associations

    News

    Trials
    Company:
    Tarapeutics Science, Youyuan Pharma
    Drug class:
    FLT3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P2, N=15, Recruiting, Tarapeutics Science Inc. | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    HYML-122
    1year
    A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P2, N=18, Recruiting, Tarapeutics Science Inc. | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • HYML-122